Clinical Trial Update: Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the immunogenicity and safety of GSK Boostrix Polio vaccine in 3- and 4-year-old children.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Poliomyelitis

Drugs mentioned

• Boostrix Polio vaccine (Diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Poliomyelitis | Phase 3 | Status: COMPLETED | Results posted: 2017-07-05